Cytotoxic T Cells Activated by Self-differentiated Monocyte- derived Dendritic Cells Against Multiple Myeloma Cells

Background/Aim: B cell maturation antigen (BCMA) is an ideal target for adoptive T cell therapy of multiple myeloma (MM). In this study, we evaluated self differentiated monocyte-derived dendritic cells expressing BCMA (SD-DC-BCMA) to activate T cells for killing MM cells. Materials and Methods: Lentivirus-modified SD-DCBCMA harboring tri-cistronic cDNAs encoding granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin4 (IL-4), and BCMA was generated. Cytotoxicity of T cells activated by SD-DC-BCMA against MM cells was evaluated. Results: T cells activated by SD-DC-BCMA exhibited a dose dependent cytotoxicity against BCMA-expressing MM cells and produced high IFN-gamma levels, compared to inactivated T cells or control T cells. A significantly higher killing ability of T cells activated by SD-DC-BCMA was further demonstrated in BCMA-overexpressing cells when compared with BCMAnegative cells. Conclusion: The potency of SD-DC-BCMA to activate T cells for antigen-specific cancer killing provides a framework for therapeutic application of adoptive T cell therapy in MM.

Automated summary

This study evaluated the effectiveness of self differentiated monocyte-derived dendritic cells expressing BCMA (SD-DC-BCMA) in activating T cells to kill multiple myeloma cells. T cells activated by SD-DC-BCMA showed dose-dependent cytotoxicity against BCMA-expressing MM cells and produced high levels of IFN-gamma.